<DOC>
	<DOCNO>NCT01703754</DOCNO>
	<brief_summary>Phase II , randomize , safety efficacy study recurrent/metastatic breast cancer accessible lesion . Primary End point rate Progression Free Survival ( PFS ) 16 week treatment time point . Hypothesis : Adenoviral vector ( Ad-RTS-hIL-12 ) alone combination chemotherapy ( palifosfamide ) safe efficacious .</brief_summary>
	<brief_title>Adenoviral Vector Monotherapy Combination With Chemotherapy Subjects With Recurrent/Metastatic Breast Cancer .</brief_title>
	<detailed_description>Multicenter , open-label , randomize study evaluate safety efficacy INXN-1001 ( veledimex ) INXN-2001 ( Ad-RTS-hIL-12 ) alone combination palifosfamide . Part 1 safety run-in safety assessment make 1 cycle therapy . Part 2 , eligible subject randomly assign active treatment Arms A C. Once monotherapy ( Arm A ) determine safe tolerable , Part 1 combination therapy ( Arm C ) begin . Subjects receive six cycle study treatment , absence meeting withdrawal criterion .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<criteria>Inclusion criterion : 1 . Males females ≥ 18 year age 2 . Histologically cytologically confirm adenocarcinoma breast , either locally recurrent metastatic disease injectable lesion , proven curative therapy exists . 3 . Failed progress least 1 prior systemic chemotherapy regimen ± biologic/experimental therapy ( firstline therapy , failure progression first 30 day ) . 4 . Resolution treatmentrelated toxicity Grade 1 severity low , except stable sensory neuropathy ≤ Grade 2 alopecia . 5 . A minimum 2 lesion ( ) assess image use mRECIST v1.1 . 6 . Eastern Cooperative Oncology Group performance status 0 , 1 , 2 7 . Male female subject must agree use highly reliable method birth control . 8 . Adequate bone marrow reserve indicate : 1 . Absolute neutrophil count &gt; 1500/μL ( without use growth factor within 7 day ) 2 . Absolute lymphocyte count &gt; 700/μL ( without use growth factor within 7 day ) 3 . Platelet count &gt; 100,000/mm3 ( without transfusion prior 7 day ) 4 . Hemoglobin &gt; 9.0 g/dL ( without transfusion prior 7 day ) 9 . Estimated glomerular filtration rate use Modification Diet Renal Disease equation : eGFR ≥ 60 mL/min/1.73 m2 10 . Adequate liver function evidence follow : 1 . Bilirubin ≤ 1.5 time upper limit normal ( ULN ) 2 . Alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) ≤ 2.5×ULN , case liver metastases ≤ 5×ULN 1 . Subjects human epidermal growth factor receptor 2 ( HER2 ) /neupositive ( immunohistochemistry [ IHC ] ) 3+ fluorescence situ hybridizationamplified ) breast tumor eligible , receive HER2targeted therapy ( eg , trastuzumab ) 2 . Concomitant anticancer therapy 3 . Prior therapy discontinuation period : 1 . Radiation within 3 week enrollment 2 . Chemotherapy within 4 week enrollment 3 . Nitrosoureas within 6 week enrollment 4 . Biologic therapy and/or immunomodulatory therapy , checkpoint inhibitor within 6 week enrollment 5 . No washout period require endocrine therapy 4 . Radiation therapy encompass &gt; 25 % bone marrow 5 . History bone marrow stem cell transplantation 6 . Any congenital acquire condition lead inability generate immune response 7 . Immunosuppressive therapy : 1 . Systemic immunosuppressive drug include corticosteroid ( prednisone equivalent &gt; 10 mg/day ) 2 . Immune suppression/requiring immunosuppressive drug , include organ allografts 3 . Active autoimmune disease require equivalent &gt; 10 mg/day prednisone 8 . Major surgery within 4 week study treatment 9 . History prior malignancy , unless prior malignancy diagnose definitively treat ≥5 year previously subsequent evidence recurrence 10 . Subjects brain subdural metastasis , unless local therapy complete corticosteroid discontinue indication ≥4 week start study treatment . 11 . Any medication induce , inhibit , substrates cytochrome P450 ( CYP450 ) 3A4 within 7 day prior first dose study drug 12 . Subjects meningeal carcinomatosis 13 . Known significant hypersensitivity study drug excipients 14 . History malabsorption syndrome condition would interfere enteral absorption 15. International Normalized Ratio ( INR ) activate partial thromboplastin time [ PTT ] &lt; 1.5 x ULN , therapeutically anticoagulated . 16 . New York Heart Association ( NYHA ) Class II great congestive heart failure OR active ventricular arrhythmia require medication 17 . Any unstable clinically significant concurrent medical condition 18 . Localized infection site injectable lesion ( ) require antiinfective therapy within 2 week first dose study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Genetically Modified Organism</keyword>
	<keyword>Metastatic Breast Cancer</keyword>
	<keyword>Recurrent Breast Cancer</keyword>
	<keyword>Breast Cancer</keyword>
	<keyword>Palifosfamide</keyword>
	<keyword>INXN1001</keyword>
	<keyword>INXN2001</keyword>
	<keyword>Adenoviral vector</keyword>
</DOC>